Transgenic Group (2342) · InitiativeFirst statedLatest Financial results (2026-08-12): "Advanced"
Improving profitability and capital efficiency through the relocation, consolidation and closure of the Kobe Research Institute
First written in FY2026. 1 of 8 entries say "Reframed", first in 2026-05-13. Latest entry: 2026-08-12.
8entries
1years
7from disclosures
How it moved
Same theme, other companies
Closure of the Kobe Research Institute and consolidation of its business functions at other sitesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-08-12AdvancedFinancial results
「However, in anticipation of the closure of the Kobe Research Institute, we advanced preparations to transfer and reallocate the functions of its genetically modified mouse business and large-animal pharmacology business, while working to reduce costs through more efficient business operations.」
The company reconfirmed that it was preparing to transfer and reallocate the functions of the genetically modified mouse and large-animal pharmacology businesses in anticipation of the closure of the Kobe Research Institute. - FY2026First statedAnnual report
「In March 2026, the Company decided to relocate or consolidate the operations of the Kobe Research Center at other sites and close the center by around December 2026, with the aim of improving profitability and capital efficiency.」
The genetically modified mouse business and large-animal pharmacology business at the Kobe Research Center will be relocated to and consolidated at other sites, with closure planned for around December 2026.